Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases

E Bahiru, AN De Cates, MRB Farr… - Cochrane Database …, 2017 - cochranelibrary.com
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death
and disability worldwide, yet ASCVD risk factor control and secondary prevention rates …

Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate–a meta-analysis of randomized trials

H Makani, S Bangalore, J Romero, N Htyte… - Journal of …, 2011 - journals.lww.com
Objective Peripheral edema is considered to be a common and annoying adverse effect of
calcium channel blockers (CCBs). It has been thought to occur secondary to arteriolar …

Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association

WS Weintraub, SR Daniels, LE Burke, BA Franklin… - Circulation, 2011 - Am Heart Assoc
The process of atherosclerosis may begin in youth and continue for decades, leading to both
nonfatal and fatal cardiovascular events, including myocardial infarction, stroke, and sudden …

Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing

E Björnsson, EI Jacobsen, E Kalaitzakis - Journal of hepatology, 2012 - Elsevier
BACKGROUND & AIMS: Limited data exist on drug-induced liver injury (DILI) associated
with statins. METHODS: Reports on adverse reactions suspected to be due to statins …

Fixed‐dose combination therapy for the prevention of cardiovascular disease

AN de Cates, MRB Farr, N Wright… - Cochrane Database …, 2014 - cochranelibrary.com
Background Cardiovascular disease (CVD) is the leading cause of death and disability
worldwide, yet CVD risk factor control and secondary prevention rates remain low. A fixed …

Some aspects of Treatment of Patients having Dislipidemia on the Background of Hypertension

IA Skoryatina, SY Zavalishina, ON Makurina… - Prensa Medica …, 2017 - elibrary.ru
At present dislipidemia and hypertension are considered as leading independent risk factors
of cardio-vascular pathology. Their effective treatment leads to significant decrease of …

Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC‐MS/MS and its application to a human pharmacokinetic study

NR Pilli, JK Inamadugu, R Mullangi… - Biomedical …, 2011 - Wiley Online Library
A rapid, simple, sensitive and specific LC‐MS/MS method has been developed and
validated for the simultaneous estimation of atorvastatin (ATO), amlodipine (AML), ramipril …

Development and validation of a liquid chromatography–tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its …

Y Zhou, J Li, X He, M Jia, M Liu, H Li, Z Xiong… - … of pharmaceutical and …, 2013 - Elsevier
A sensitive, simple and rapid high-performance liquid chromatography coupled with positive
ion electrospray ionization-tandem mass spectrometry (HPLC–ESI-MS/MS) method was …

A novel programme to evaluate and communicate 10‐year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile

JS Benner, L Erhardt, M Flammer… - … journal of clinical …, 2008 - Wiley Online Library
Aims: We assessed whether a novel programme to evaluate/communicate predicted
coronary heart disease (CHD) risk could lower patients' predicted Framingham CHD risk vs …

Atorvastatin for lowering lipids

SP Adams, M Tsang, JM Wright - Cochrane Database of …, 2015 - cochranelibrary.com
Background This represents the first update of this review, which was published in 2012.
Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin …